Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV E6/E7 DC Vaccine for CIN1/CIN2
NCT03870113Phase 1Unknown
- Sponsor
- Shenzhen People's Hospital
- Start
- Apr 2019
- Primary completion
- Mar 2022
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of human papillomavirus 16/18 E6/E7-targeted dendritic cell vaccine in cervical intraepithelial neoplasia (CIN), sponsored by Shenzhen People's Hospital. Primary endpoints: Incidence of Treatment-Emergent Adverse Events and Immunogenicity of neoantigen-primed DC Vaccines. Status: unknown.
02
Drugs
human papillomavirus 16/18 E6/E7-targeted dendritic cell vaccine
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT03870113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870113.